Patents by Inventor Stefan Limmer

Stefan Limmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180179526
    Abstract: The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.
    Type: Application
    Filed: January 12, 2018
    Publication date: June 28, 2018
    Inventors: Roland Kreutzer, Stefan Limmer
  • Patent number: 9902955
    Abstract: The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: February 27, 2018
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer
  • Patent number: 9902954
    Abstract: The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: February 27, 2018
    Assignee: Alynylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer
  • Patent number: 9587240
    Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3?-end and a blunt 5?-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: March 7, 2017
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer, Sylvia Limmer, Philipp Hadwiger
  • Publication number: 20150353937
    Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3?-end and a blunt 5?-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.
    Type: Application
    Filed: June 11, 2015
    Publication date: December 10, 2015
    Inventors: Roland Kreutzer, Stefan Limmer, Sylvia Limmer, Philipp Hadwiger
  • Patent number: 9133454
    Abstract: The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: September 15, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer
  • Patent number: 9074213
    Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3?-end and a blunt 5?-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: July 7, 2015
    Assignee: Alnylam Pharmacuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer, Sylvia Limmer, Philipp Hadwiger
  • Patent number: 8877726
    Abstract: The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: November 4, 2014
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer
  • Publication number: 20140220676
    Abstract: The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.
    Type: Application
    Filed: March 18, 2014
    Publication date: August 7, 2014
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer
  • Publication number: 20140220113
    Abstract: The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.
    Type: Application
    Filed: March 18, 2014
    Publication date: August 7, 2014
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer
  • Patent number: 8729037
    Abstract: The present invention relates to the specific inhibition of expression of a target gene in mammals using a short double stranded RNA. The dsRNA is less than 49 nucleotides in length and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases, for example, cancer, viral diseases or neurodegenerative diseases.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: May 20, 2014
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer
  • Publication number: 20140106450
    Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3?-end and a blunt 5?-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.
    Type: Application
    Filed: August 28, 2013
    Publication date: April 17, 2014
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer, Sylvia Limmer, Philipp Hadwiger
  • Publication number: 20140051166
    Abstract: The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.
    Type: Application
    Filed: October 19, 2012
    Publication date: February 20, 2014
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Roland Kreutzer, Stefan Limmer
  • Patent number: 8546143
    Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3?-end and a blunt 5?-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: October 1, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer, Sylvia Limmer, Philipp Hadwiger
  • Publication number: 20130064879
    Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3?-untranslated region (3?-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.
    Type: Application
    Filed: August 24, 2012
    Publication date: March 14, 2013
    Inventors: Matthias John, Stefan Limmer, Hans-Peter Vornlocher, Roland Kreutzer
  • Publication number: 20120322858
    Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a first strand that has a complementary region that is complementary to at least a portion of an RNA transcript of at least part of the mutant target gene and a second strand of the dsRNA complementary or substantially complementary to the first strand. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.
    Type: Application
    Filed: August 24, 2012
    Publication date: December 20, 2012
    Inventors: Roland Kreutzer, Stefan Limmer, Matthias John
  • Patent number: 8273868
    Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3?-untranslated region (3?-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: September 25, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Matthias John, Stefan Limmer, Hans-Peter Vornlocher, Roland Kreutzer
  • Patent number: 8273870
    Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a first strand that has a complementary region that is complementary to at least a portion of an RNA transcript of at least part of the mutant target gene and a second strand of the dsRNA complementary or substantially complementary to the first strand. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: September 25, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer, Matthias John
  • Patent number: 8202980
    Abstract: The present invention provides methods and compositions for inhibiting gene expression using double stranded RNA molecules that are between 15 and 21 nucleotides in length and are complementary to a target gene sequence.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: June 19, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer
  • Patent number: 8183362
    Abstract: The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: May 22, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer